Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 152-158

  Iizuka, Norio ^a   Oka, Masaaki ^a   Sakaida, Isao ^a   Moribe, Toyoki ^b   Miura, Toshiaki ^b   Kimura, Naoki ^b   Tamatsukuri, Shigeru ^b   Ishitsuka, Hideo ^a   Uchida, Koichi ^a   Terai, Shuji ^c   Yamashita, Satoyoshi ^c   Okita, Kiwamu ^c   Sakata, Koichiro ^d   Karino, Yoshiyasu ^d   Toyota, Joji ^e   Ando, Eiji ^e   Ide, Tatsuya ^e   Sata, Michio ^a   Tsunedomi, Ryoichi ^a   Tsutsui, Masahito ^a   Iida, Michihisa ^a   Tokuhisa, Yoshihiro ^a   Sakamoto, Kazuhiko ^a   Tamesa, Takao ^a   Fujita, Yusuke ^f   Hamamoto, Yoshihiko ^f   more..

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Molecular Diagnostics Division   (Japan)

^c Shimonoseki Welfare Social Hospital   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Blood testing; Cell free DNA; HCC; HCV; Hybrid detector; Hypermethylation; Quantitative MSP

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTEIN SPINT2; PROTHROMBIN INDUCED VITAMIN K ABSENCE II; STEROID 5ALPHA REDUCTASE 2; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DNA METHYLATION; EPIGENETICS; FEMALE; GENETIC DATABASE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULAR HYBRIDIZATION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VITAMIN K DEFICIENCY;

AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; PROTEIN PRECURSORS; PROTHROMBIN; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS C VIRUS;

EID: 78650516039     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.028     Document Type: Article

References (36)

1. Deuffic S., Poynard T., Buffat L., Valleron A.J. Trends in primary liver cancer. Lancet 1998, 351:214-215.
2. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
4. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
5. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
6. Poynard T., Yuen M.F., Ratziu V., Lai C.L. Viral hepatitis C. Lancet 2003, 362:2095-2100.
7. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
8. Gupta S., Bent S., Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003, 139:46-50.
9. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
10. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
11. Kanai Y., Hui A.M., Sun L., Ushijima S., Sakamoto M., Tsuda H., et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999, 29:703-709.
12. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001, 28:29-35.
13. Fukai K., Yokosuka O., Chiba T., Hirasawa Y., Tada M., Imazeki F., et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 2003, 63:8674-8679.
14. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007, 13:2378-2384.
15. Wong I.H., Zhang J., Lai P.B., Lau W.Y., Lo Y.M. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 2003, 9:1047-1052.
16. Moribe T., Iizuka N., Miura T., Stark M., Tamatsukuri S., Ishitsuka H., et al. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol 2008, 33:949-958.
17. Moribe T., Iizuka N., Miura T., Kimura N., Tamatsukuri S., Ishitsuka H., et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009, 125:388-397.
18. Dupuy A., Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99:147-157.
19. Iizuka N., Oka M., Yamada-Okabe H., Nishida M., Maeda Y., Mori N., et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003, 361:923-929.
20. Ikai I., Takayasu K., Omata M., Okita K., Nakanuma Y., Matsuyama Y., et al. Liver Cancer Study Group of Japan. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006, 41:884-892.
21. Giannelli G., Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis 2006, 38:854-859.
22. Iizuka N., Sakaida I., Moribe T., Fujita N., Miura T., Stark M., et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006, 26:4713-4719.
23. Oka H., Saito A., Ito K., Kumada T., Satomura S., Kasugai H. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001, 16:1378-1383.
24. Kasahara A., Hayashi N., Fusamoto H., Kawada Y., Imai Y., Yamamoto H., et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993, 38:2170-2176.
25. Marrero J.A., Feng Z., Wang Y., Nguyen M.H., Befeler A.S., Roberts L.R., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
26. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
27. Mita Y., Aoyagi Y., Yanagi M., Suda T., Suzuki Y., Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998, 82:1643-1648.
28. Debruyne E.N., Joris R., Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008, 395:19-26.
29. Ntzani E.E., Ioannidis J.P. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003, 362:1439-1444.
30. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008, 358:1118-1128.
31. Müller H.M., Oberwalder M., Fiegl H., Morandell M., Goebel G., Zitt M., et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 2004, 363:1283-1285.
32. Hoque M.O., Topaloglu O., Begum S., Henrique R., Rosenbaum E., Van Criekinge W., et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005, 23:6569-6575.
33. Chan K.C., Lai P.B., Mok T.S., Chan H.L., Ding C., Yeung S.W., et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008, 54:1528-1536.
34. Morris M.R., Gentle D., Abdulrahman M., Maina E.N., Gupta K., Banks R.E., et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005, 65:4598-4606.
35. Ntais C., Polycarpou A., Ioannidis J.P. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 2003, 12:618-624.
36. Iizuka N., Hamamoto Y., Oka M. Prediction of cancer outcome with microarrays. Lancet 2005, 365:1683-1684.